ClinicalTrials.gg
Not yet recruitingNCT07449156Updated Mar 4, 2026

A Study to Evaluate Efficacy and Safety of HB0043 in Aadult Patients With Moderate to Severe Acne Vulgaris.

A Phase 1/2 interventional study of HB0043 and Placebo in Acne Vulgaris, sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies in Acne Vulgaris with a site in China — 8 open to participants now, 10 under way, 2 of them phase 3. Acne Vulgaris · China.

Planned enrollment
29th of 33
21 · median 100
Started
2026
the only one that year
Phase 1/2
3 of 35
1 open now
Registered
34th of 35
by date

Among the 35 studies in Acne Vulgaris with a site in China, this one is the 29th largest by planned enrollment of the 33 interventional ones that give a count, is the only one that started in 2026, is one of 3 in phase 1/2, and was the 34th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

8 of the 35 studies in Acne Vulgaris with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Acne Vulgaris with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe AV.

Read the detailed description

The total duration of the study is 18 weeks and consists of: Screening (up to 2 weeks) and Treatment Period (16 weeks).

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- 1. Understand the research procedure of this study and provide written ; 2. Male or female, age 18 years or greater; 3. Diagnosed with mild to moderate facial acne vulgaris; 4. Throughout the study period, participants must refrain from using concomitant acne therapies.

5. Acceptance by the patient, of childbearing age, to use safe methods throughout the study, including 3 months of follow-up.

Exclusion criteria

Exclusion Criteria:

  • 1. Participants with known to HB0043 or any of its ; 2. Those with facial skin or hair conditions, or with facial skin damage or abnormality that may interfere with clinical assessment.

    3. Participant has any facial skin disease other than common acne. 4. Presence of other active diseases, including but not limited to psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and uveitis; 5. Participant has any other active skin disease or condition that may interfere with the assessment of acne vulgaris; 6. History of lymphoproliferative disorders or any known within five years prior to the Screening Visit (excluding treated and cured cutaneous squamous cell carcinoma, basal cell carcinoma, carcinoma uterine in situ, or intraductal breast cancer in situ); 7. History of recurrent or recent serious infection; 8. Participant has active tuberculosis (TB) or concurrent treatment for latent TB or evidence of virus (HBV) or virus (HCV) or (HIV) infection; 9. Pregnant or lactating women; 10. Any reason why, in the opinion of the investigator, the patient should not participate.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Care provider)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    HB0043

    Participants randomized to Arm 1 will receive HB0043 via subcutaneous injection biweekly from Week 0 to Week 14.

    Drug: HB0043

  • Experimental
    Placebo

    Participants randomized to Arm 2 will receive placebo via subcutaneous injection biweekly from Week 0 to Week 6, followed by HB0043 via subcutaneous injection biweekly from Week 8 to Week 14.

    Drug: HB0043 · Drug: Placebo

Interventions

  • DrugHB0043

    300mg

  • DrugPlacebo

    300mg

06

What researchers measure

Primary outcomes

  1. Change in inflammatory lesion counts

    Absolute change from Baseline in the number of inflammatory acne lesions

    Time frame: Week 16

  2. Investigator's global assessment (IGA) - change from Baseline

    Absolute change in IGA score from Baseline \[scores: 0-4; 0=clear, 4=severe\]

    Time frame: Week 16

Secondary outcomes

  1. Investigator's global assessment (IGA) - percentage of subjects with improvement

    Percentage of subjects with at least two-grade improvement in their Baseline IGA score (assessment of mild, clear or almost clear) \[scores: 0-4; 0=clear, 4=severe\]

    Time frame: Week 2, 4, 8, 12, 16

  2. Change in inflammatory lesion counts

    Percentage change from Baseline in the number of inflammatory acne lesions

    Time frame: Week 16

  3. Investigator's global assessment (IGA) - percentage of subjects with improvement

    Percentage of subjects with an IGA score of "clear" or "almost clear"

    Time frame: Week 2, 4, 8, 12, 16

  4. Investigator's global assessment (IGA) - percentage of subjects with improvement

    Percentage of subjects with an IGA score of "clear" or "almost clear" and a reduction of at least two-grade compared to the baseline IGA score.

    Time frame: Week 2, 4, 8, 12, 16

  5. Incidence of AEs and serious adverse events (SAEs))

    Incidence of AEs and SAEs

    Time frame: Baseline to week 16

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Oct 2026, 7 months later.

Of 13 phase 1/2 interventional studies under Acne Vulgaris, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 22. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 4, 2026
StartEst.
Mar 27, 2026
Primary completionEst.
Oct 27, 2026
CompletionEst.
Mar 27, 2027
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07449156
Lead sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Collaborators
Dermatology Hospital affiliated to Shandong First Medical University
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Mar 27, 2026 (estimated)
Primary completion
Oct 27, 2026 (estimated)
Completion
Mar 27, 2027 (estimated)
Last update
Mar 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HB0043

Start the discussion